$Tevogen Bio Holdings (TVGN.US)$
20/11/2024 - 05:50
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.
Significantly improved financial position by eliminating nearly all of its...
20/11/2024 - 05:50
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.
Significantly improved financial position by eliminating nearly all of its...
2
$ZenaTech (ZENA.US)$
19/11/2024 - 20:30
TORONTO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, announces today that it will pursue a series of acquisitions to launch its Drone-as-a-Service (DaaS) operations. These acquisitions have the potential to ...
19/11/2024 - 20:30
TORONTO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, announces today that it will pursue a series of acquisitions to launch its Drone-as-a-Service (DaaS) operations. These acquisitions have the potential to ...
2
1
$Conduit Pharmaceuticals (CDT.US)$
Simon’s depth of experience in capital markets and investment strategy brings tremendous value to Conduit as we expand our pipeline and explore new opportunities for growth,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “We are thrilled to welcome Simon to the Board and look forward to leveraging his expertise to enhance our strategic initiatives and maximize shareholder value.”
Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry | CDT Stock News
Simon’s depth of experience in capital markets and investment strategy brings tremendous value to Conduit as we expand our pipeline and explore new opportunities for growth,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “We are thrilled to welcome Simon to the Board and look forward to leveraging his expertise to enhance our strategic initiatives and maximize shareholder value.”
Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry | CDT Stock News
4